VintaBio
Biotechnology ResearchPennsylvania, United States11-50 Employees
Scalable adherent viral vector manufacturing for clinical-stage gene therapy programs. VintaBio is a viral vector development and manufacturing partner supporting biotech and pharmaceutical companies advancing AAV, LVV, Adeno, Vero-based, vaccine, and other viral vector programs into clinical development. We specialize in scalable adherent manufacturing, process development, and clinical material generation for programs progressing through Phase 1, Phase 2, and Phase 3. As gene therapy and vaccine programs move from early development into clinical execution, upstream manufacturing decisions become critical to: • Clinical timeline predictability • Process validation success • Capsid quality and yield optimization • Regulatory readiness • Long-term commercial scalability Our approach combines validated fixed-bed bioreactor platforms with the option to integrate perfusion technologies, enabling: • Deeper visibility into cell line kinetics • Improved cell viability and harvest timing precision • Cleaner upstream material profiles • Higher full capsid percentages for AAV • More consistent clinical supply generation We work closely with development, CMC, and technical operations teams to reduce scale-up risk, strengthen process control, and accelerate programs toward the clinic — particularly in rare and genetically defined diseases where speed and reliability matter most. Headquartered in the Philadelphia Navy Yard — a leading hub for cell and gene therapy innovation — VintaBio is committed to advancing high-quality, scalable viral vector manufacturing solutions that support both clinical success and long-term patient impact. To learn more: www.vintabio.com
1-888-653-2347 
support@leadiq.com 
